Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Neurodegenerative Disease Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 NMDA
  • 1.3.3 SSRIs
  • 1.3.4 Dopamine Inhibitors
• 1.4 Market Segment by Application
  • 1.4.1 Global Neurodegenerative Disease Market Share by Application (2019-2025)
  • 1.4.2 Parkinson’s Disease
  • 1.4.3 Huntington Disease
  • 1.4.4 Amyotrophic Lateral Sclerosis
  • 1.4.5 Alzheimer’s Disease
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Neurodegenerative Disease Market Size
  • 2.1.1 Global Neurodegenerative Disease Revenue 2014-2025
  • 2.1.2 Global Neurodegenerative Disease Sales 2014-2025
• 2.2 Neurodegenerative Disease Growth Rate by Regions
  • 2.2.1 Global Neurodegenerative Disease Sales by Regions 2014-2019
  • 2.2.2 Global Neurodegenerative Disease Revenue by Regions 2014-2019
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Neurodegenerative Disease Sales by Manufacturers
  • 3.1.1 Neurodegenerative Disease Sales by Manufacturers 2014-2019
  • 3.1.2 Neurodegenerative Disease Sales Market Share by Manufacturers 2014-2019
• 3.2 Revenue by Manufacturers
  • 3.2.1 Neurodegenerative Disease Revenue by Manufacturers (2014-2019)
  • 3.2.2 Neurodegenerative Disease Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Neurodegenerative Disease Market Concentration Ratio (CR5 and HHI)
• 3.3 Neurodegenerative Disease Price by Manufacturers
• 3.4 Key Manufacturers Neurodegenerative Disease Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Neurodegenerative Disease Market
• 3.6 Key Manufacturers Neurodegenerative Disease Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Sales and Revenue for Each Type
  • 4.1.1 NMDA Sales and Revenue (2014-2019)
  • 4.1.2 SSRIs Sales and Revenue (2014-2019)
  • 4.1.3 Dopamine Inhibitors Sales and Revenue (2014-2019)
• 4.2 Global Neurodegenerative Disease Sales Market Share by Type
• 4.3 Global Neurodegenerative Disease Revenue Market Share by Type
• 4.4 Neurodegenerative Disease Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Neurodegenerative Disease Sales by Application

6 United States

• 6.1 United States Neurodegenerative Disease Breakdown Data by Company
• 6.2 United States Neurodegenerative Disease Breakdown Data by Type
• 6.3 United States Neurodegenerative Disease Breakdown Data by Application

7 European Union

• 7.1 European Union Neurodegenerative Disease Breakdown Data by Company
• 7.2 European Union Neurodegenerative Disease Breakdown Data by Type
• 7.3 European Union Neurodegenerative Disease Breakdown Data by Application

8 China

• 8.1 China Neurodegenerative Disease Breakdown Data by Company
• 8.2 China Neurodegenerative Disease Breakdown Data by Type
• 8.3 China Neurodegenerative Disease Breakdown Data by Application

9 Rest of World

• 9.1 Rest of World Neurodegenerative Disease Breakdown Data by Company
• 9.2 Rest of World Neurodegenerative Disease Breakdown Data by Type
• 9.3 Rest of World Neurodegenerative Disease Breakdown Data by Application
• 9.4 Rest of World Neurodegenerative Disease Breakdown Data by Countries
  • 9.4.1 Rest of World Neurodegenerative Disease Sales by Countries
  • 9.4.2 Rest of World Neurodegenerative Disease Revenue by Countries
  • 9.4.3 Japan
  • 9.4.4 Korea
  • 9.4.5 India
  • 9.4.6 Southeast Asia

10 Company Profiles

• 10.1 Novartis
  • 10.1.1 Novartis Company Details
  • 10.1.2 Company Description and Business Overview
  • 10.1.3 Sales, Revenue and Market Share of Neurodegenerative Disease
  • 10.1.4 Neurodegenerative Disease Product Introduction
  • 10.1.5 Novartis Recent Development
• 10.2 Pfizer
  • 10.2.1 Pfizer Company Details
  • 10.2.2 Company Description and Business Overview
  • 10.2.3 Sales, Revenue and Market Share of Neurodegenerative Disease
  • 10.2.4 Neurodegenerative Disease Product Introduction
  • 10.2.5 Pfizer Recent Development
• 10.3 Merck Serono
  • 10.3.1 Merck Serono Company Details
  • 10.3.2 Company Description and Business Overview
  • 10.3.3 Sales, Revenue and Market Share of Neurodegenerative Disease
  • 10.3.4 Neurodegenerative Disease Product Introduction
  • 10.3.5 Merck Serono Recent Development
• 10.4 Biogen Idec
  • 10.4.1 Biogen Idec Company Details
  • 10.4.2 Company Description and Business Overview
  • 10.4.3 Sales, Revenue and Market Share of Neurodegenerative Disease
  • 10.4.4 Neurodegenerative Disease Product Introduction
  • 10.4.5 Biogen Idec Recent Development
• 10.5 TEVA
  • 10.5.1 TEVA Company Details
  • 10.5.2 Company Description and Business Overview
  • 10.5.3 Sales, Revenue and Market Share of Neurodegenerative Disease
  • 10.5.4 Neurodegenerative Disease Product Introduction
  • 10.5.5 TEVA Recent Development
• 10.6 UCB
  • 10.6.1 UCB Company Details
  • 10.6.2 Company Description and Business Overview
  • 10.6.3 Sales, Revenue and Market Share of Neurodegenerative Disease
  • 10.6.4 Neurodegenerative Disease Product Introduction
  • 10.6.5 UCB Recent Development
• 10.7 Boehringer Ingelheim
  • 10.7.1 Boehringer Ingelheim Company Details
  • 10.7.2 Company Description and Business Overview
  • 10.7.3 Sales, Revenue and Market Share of Neurodegenerative Disease
  • 10.7.4 Neurodegenerative Disease Product Introduction
  • 10.7.5 Boehringer Ingelheim Recent Development
• 10.8 Sanofi
  • 10.8.1 Sanofi Company Details
  • 10.8.2 Company Description and Business Overview
  • 10.8.3 Sales, Revenue and Market Share of Neurodegenerative Disease
  • 10.8.4 Neurodegenerative Disease Product Introduction
  • 10.8.5 Sanofi Recent Development
• 10.9 GlaxoSmithKline
  • 10.9.1 GlaxoSmithKline Company Details
  • 10.9.2 Company Description and Business Overview
  • 10.9.3 Sales, Revenue and Market Share of Neurodegenerative Disease
  • 10.9.4 Neurodegenerative Disease Product Introduction
  • 10.9.5 GlaxoSmithKline Recent Development

11 Value Chain and Sales Channels Analysis

• 11.1 Value Chain Analysis
• 11.2 Sales Channels Analysis
  • 11.2.1 Neurodegenerative Disease Sales Channels
  • 11.2.2 Neurodegenerative Disease Distributors
• 11.3 Neurodegenerative Disease Customers

12 Market Forecast

• 12.1 Global Neurodegenerative Disease Sales and Revenue Forecast 2019-2025
• 12.2 Global Neurodegenerative Disease Sales Forecast by Type
• 12.3 Global Neurodegenerative Disease Sales Forecast by Application
• 12.4 Neurodegenerative Disease Forecast by Regions
  • 12.4.1 Global Neurodegenerative Disease Sales Forecast by Regions 2019-2025
  • 12.4.2 Global Neurodegenerative Disease Revenue Forecast by Regions 2019-2025
• 12.5 United States Market Forecast
• 12.6 European Union Market Forecast
• 12.7 China Market Forecast
• 12.8 Rest of World
  • 12.8.1 Japan
  • 12.8.2 Korea
  • 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
  • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
• 14.2 Author Details

Neurodegenerative disease or neurodegeneration refers to the progressive damage or wear and tear of the nerve cells. Neurodegenerative disease causes loss of abilities like decision making and eventually memory loss.
In 2019, the market size of Neurodegenerative Disease is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Neurodegenerative Disease.

This report studies the global market size of Neurodegenerative Disease, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Neurodegenerative Disease sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Novartis
Pfizer
Merck Serono
Biogen Idec
TEVA
UCB
Boehringer Ingelheim
Sanofi
GlaxoSmithKline

Market Segment by Product Type
NMDA
SSRIs
Dopamine Inhibitors

Market Segment by Application
Parkinson’s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Alzheimer’s Disease

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Neurodegenerative Disease status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Neurodegenerative Disease manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Neurodegenerative Disease are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025